F10 and ovarian cancer: We sought to establish whether FX could be detected in the ascites from patients with ovarian cancer by enzyme-linked immunosorbent assay, to establish whether FX might be a potential barrier to Ad transduction of tumor cells when delivered intraperitoneally.